MyFiziq June quarter ends on a high with receipt of US$450,000
MyFiziq Limited (ASX:MYQ) has received the tranche 2 payment of US$450,000 under the convertible note subscription deed announced with Asia Cornerstone Asset Management.
As announced on June 1, 2020, under the terms of the Convertible Note Subscription Deed with ACAM, MYQ was entitled to receive a total of US$1.5 million in 4 tranches, at this payment of US$450,000 represents the tranche two disbursement.
Management said that it was pleased with the progress made this quarter on several fronts.
The company highlighted these sentiments in an extremely positive update on the group’s operational performance in the last three months, highlighting MyFiziq’s highly promising outlook as it enters fiscal 2021.
As featured in finfeed yesterday, there have been numerous strategic developments on many fronts with important collaborative deals struck which will see broader applications of the company’s technologies, together with marketing arrangements which should see the group’s body measurement technology embraced by millions of people.
In brief, these operational and financial milestones can be summarised as follows.
Targeting multiple markets
Importantly, potential users of the technologies come from a wide range of sectors and demographics as it has applications for government and corporate organisations, as well as uses in the medical field, right through to personal monitoring, particularly in the health and fitness arena.
MyFiziq has developed this capability by leveraging the power of computer vision, machine learning, and patented algorithms, to process these images on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivalled in the industry.
Body measurements provide more important information about health, risk and physical change than simply measuring weight.
MyFiziq simplifies the collection of these measurements, conveniently and cost-effectively, whilst removing the margin of human error present in traditional methods.
Investors have understood the significant upside potential as the company enters fiscal 2021 with its shares having soared from approximately 7 cents towards the end of March to close at 30 cents on June 9, a level that they are again pushing up towards despite volatility in broader equity markets.
The following chart demonstrates the significant outperformance over the last three months against the S&P/ASX All Ordinaries index (XAO - green line).
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.